HTLV-I Quantification

<<Return to Search Results

The National Laboratory for HIV Reference Services is accredited to ISO 15189 by the Standards Council of Canada for the specific scopes of accreditation published on www.scc.ca.

Requisition Forms

Reference Details

Description:

HTLV-I Quantification

Test Category:
Molecular Quantification
Pathogen:
Human T-lymphotropic virus (HTLV)
Illnesses and Diseases:
  • Adult T-cell leukemia/lymphoma (ATLL)
Specimen:

EDTA whole blood; 5mL (minimum 2mL with the exception of babies).  Contact NLHRS for specimens other than those listed.  Note: Specimens categorized as “other” are not subject to accreditation by the Standards Council of Canada for the specific scopes of accreditation published on www.scc.ca.

Collection Method:

See specimen above.

Specimen Processing, Storage and Shipping:

Ambient temperature (received within 48 hours of collection).

Transportation of Dangerous Goods:

Shipping of specimens shall be done by a TDG certified individual in accordance with TDG regulations. For additional information regarding classification of specimens for the purposes of shipping, consult either Part 2 Appendix 3 of the TDG Regulations or section 3.6.2 of the IATA Dangerous Goods Regulations as applicable.

For additional guidance on the transport of infectious substances in other languages, please click on the link below.

http://www.who.int/ihr/capacity-strengthening/infectious-substances/en/

 

Patient Criteria:

Please provide risk factors.

Accompanying Documentation:

NLHRS HTLV I/II Requisition: PCR, Serology & Viral Load

Comments:
  • See attached NLHRS Submission Guidelines.
Methods and Interpretation of Results:

Varies for each test method, contact NLHRS for further information.

Turnaround Time:

Varies for each test method, contact NLHRS for further information.

Contact:
Phone: (204) 789-6523 or (204) 789-6522
Fax: (204) 318-2221
References:
  1. Standard Council of Canada. SCC accredits first medical laboratory under new national program.  2008. http://www.scc.ca/en/news-events/news/2008/scc-accredits-first-medical-laboratory-under-new-national-program
  2. S.Lavoie, D. Caswell, M.J. Gill, K. Kadkhoda, C.L Charlton, P.N. Levett, T.Hatchette, R. Garceau, J. Maregmen, T. Mazzulli, R. Needle, K. Kadivar, J. Kim. Heterophilic interference in specimens yielding false-reactive results on the Abbott 4th generation ARCHITECT HIV Ag/Ab Combo Assay. Journal of Clinical Virology. 2018;104: 23-28
  3. Malloch L, Kadivar K, Putz J, Levett PN, Tang J, Hatchette TF, Kadkhoda K, Ng D, Ho J, Kim J. Comparative Evaluation of the Bio-Rad Geenius HIV-1/2 Confirmatory Assay and the BioRrad Multispot HIV-1/2 Rapid Test as an Alternative Differentiation Assay for CLSI M53 Algorithm-I. Journal of Clinical Virology. 2013;58, Supplement 1(0):e85-e91. http://www.sciencedirect.com/science/article/pii/S1386653213003326
  4. Kadivar K, Malloch L, Adonsou-Hoyi Y, Ng D, Lavoie S, Pulido K, Kim J. Would CLSI M53-A Have Helped in the Diagnosis of HIV in Canada? Results of the Performance of Canadian Laboratories Participating in a Recent NLHRS Proficiency Testing Panel Containing HIV-1 Antigen Positive (Antibody Negative) and HIV-2 Samples. Journal of Clinical Virology. 2013;58(1):303-305. http://www.sciencedirect.com/science/article/pii/S1386653213001303
Related Information: